A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein.
Tang, A., Chen, Z., Cox, K.S., Su, H.P., Callahan, C., Fridman, A., Zhang, L., Patel, S.B., Cejas, P.J., Swoyer, R., Touch, S., Citron, M.P., Govindarajan, D., Luo, B., Eddins, M., Reid, J.C., Soisson, S.M., Galli, J., Wang, D., Wen, Z., Heidecker, G.J., Casimiro, D.R., DiStefano, D.J., Vora, K.A.(2019) Nat Commun 10: 4153-4153
- PubMed: 31515478 
- DOI: https://doi.org/10.1038/s41467-019-12137-1
- Primary Citation of Related Structures:  
6OUS - PubMed Abstract: 
Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant mortality under six months of age worldwide; therefore, the prevention of RSV infection in all infants represents a significant unmet medical need. Here we report the isolation of a potent and broadly neutralizing RSV monoclonal antibody derived from a human memory B-cell ...